Latest news

ERS Genomics and StemSight sign CRISPR/Cas9 license agreement

  License agreement provides StemSight access to CRISPR/Cas9 technology to be applied in development of cell therapies for corneal blindness Dublin, Ireland, and Tampere, Finland, 17 January 2024: ERS Genomics Limited (‘ERS’), the CRISPR licensing Company, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr Emmanuelle Charpentier, and StemSight Oy (‘StemSight’), a biotechnology company developing stem cell based therapies for corneal blindness, today announced a non-exclusive CRISPR/Cas9 license agreement. The agreement grants StemSight access to ERS’ CRISPR/Cas9 patent portfolio. StemSight is a preclinical biotechnology company developing off-the-shelf cell therapies for unmet medical needs

Read more
News

Top news